<u>COVID-19 Trials</u> Clinical Trials – November 2020

Eugene M. and Christine E. Lynn Office of Research Administration **561.955.4800** Boca Raton Regional Hospital 561.955.7100

	COVID-19		
Primary Site	Sponsor/Study ID NCT #	Protocol Description	Eligibility
COVID 19 Symptoms	Regeneron R10933-10987- COV-2066 NCT04426695	A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-COV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients with COVID-19	 Cohort 1A: With COVID-19 symptoms but not requiring supplemental oxygen Cohort 1: O2 saturation >93% on low-flow oxygen via nasal cannula, simple face mask, or other similar device For both cohorts: ≥18 years of age Positive molecular test for COVID 19 ≤72 hours prior to randomization Onset of Symptoms ≤10 days Hospitalized due to COVID 19 No pregnant or breastfeeding women No prior convalescent plasma Willing to use contraception at least 6 months after the last dose
COVID 19 Respiratory Symptoms	Duke University NCT04399889	Pilot Study of Safety and Efficacy of Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC) in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)	 ≥18 years of age Positive molecular testing for COVID 19 Criteria for Acute Respiratory Symptoms No pregnant or breastfeeding women No signs of multi-organ failure

Updated: 02Nov2020

<u>COVID-19 Trials</u> Clinical Trials – November 2020

Eugene M. and Christine E. Lynn Office of Research Administration **561.955.4800** Boca Raton Regional Hospital 561.955.7100

COVID 19	The Ohio State	Phase II Protocol of Low-Dose Whole Thorax	•	≥50 years of age
Respiratory	University	Megavoltage Radiotherapy for Patients with SARS-CoV-	•	Hospitalized due to COVID 19
Symptoms	PreVent	2 Pneumonia	•	Onset of symptoms ≤ 9 days Diagnosis of COVID related pneumonia
	rievent			Not on ventilator use
	NCT04466683			No female pregnant or breastfeeding
	1101010005			Two remains programs or oreastreeding

Updated: 02Nov2020